🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

545 results for “B.” Clear

  1. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Bipolar I Disorder

    phase 3 small molecule completed

    2 trials

  2. Imetelstat

    Geron Netherlands B.V.

    Myelofibrosis

    phase 3 small molecule active

    1 trial

  3. Intermittent hepatic inflow occlusion (IHIO)

    Samsung Bioepis NL B.V.

    End Stage Liver Disease

    phase 3 other active

    1 trial

  4. KALOMIN™ Tab.

    United Therapeutics Europe Ltd

    Acute Bronchitis

    phase 3 small molecule completed

    1 trial

  5. KB803

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Samsung Bioepis NL B.V.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR

    Orchard Therapeutics (Netherlands) B.V.

    Mucopolysaccharidosis type I, Hurler Syndrome

    phase 3 small molecule active

    1 trial

  8. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  9. LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT

    Stemline Therapeutics B.V.

    Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

    phase 3 small molecule active

    1 trial

  10. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations

    phase 3 small molecule active

    1 trial

  11. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD)

    phase 3 small molecule active

    1 trial

  12. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  13. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

  14. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

  15. MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph

    Iovance Biotherapeutics B.V.

    Melanoma

    phase 3 small molecule active

    1 trial

  16. MaaT013

    Lacuna Pharma Pty Ltd

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

  17. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    3 trials

  18. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

    phase 3 small molecule active

    1 trial

  19. Medtronic Talent Stent-Graft-System

    Rhythm Pharmaceuticals Netherlands B.V.

    Aortic Diseases

    phase 3 other completed

    1 trial

  20. Milsaperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder (MDD)

    phase 3 small molecule active

    1 trial

  21. Mitapivat

    Agios Netherlands B.V.

    Sickle Cell Disease

    phase 3 small molecule active

    2 trials

  22. Mitapivat

    Agios Netherlands B.V.

    Pediatric Pyruvate Kinase Deficiency

    phase 3 small molecule active

    2 trials

  23. Mitapivat

    Agios Netherlands B.V.

    Non-Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  24. Mitapivat Matched Placebo

    Agios Netherlands B.V.

    Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources